One in Four Cancer Patients Stop Treatment Because of High Costs — Here’s What the Research Shows

A cancer diagnosis is devastating enough. But for a staggering share of patients, a second crisis follows the first: the bill. Across multiple published studies, roughly one in four cancer patients end up skipping, delaying, or abandoning part of their prescribed treatment simply because they cannot afford it. Doctors have a clinical name for this phenomenon — “financial toxicity” — and the research suggests it is as real a threat to survival as any side effect.

What the numbers actually say

The headline figure comes from peer-reviewed research that has been reported by outlets including KFF Health News. A 2013 study published in the journal The Oncologist found that 24 percent of cancer patients chose not to fill a prescription at all because of cost, while about 20 percent filled only part of a prescription or took less than the prescribed amount. A separate study published in the journal Cancer found similar patterns: roughly 10 percent skipped medication or took less than prescribed, and 14 percent delayed filling a prescription.

The problem is not confined to general oncology surveys. A study in the Journal of Clinical Oncology found that one-third of Medicare patients expected to use Gleevec — a lifesaving leukemia drug costing over $100,000 a year — failed to fill their prescriptions within six months of diagnosis. Research led by Stacie Dusetzina at the University of North Carolina found that privately insured patients with higher monthly copayments were 70 percent more likely to stop taking the drug or take fewer doses than prescribed.

Writing in 2023, an oncologist reviewing the evidence concluded that over a quarter of cancer patients delay care, go without care, or change their cancer treatment because of cost. A policy review by the Baker Institute put the range at 20 to 35 percent of patients delaying, abandoning, or compromising treatment over affordability. The figures vary by country, cancer type, and insurance setup — but the one-in-four pattern keeps reappearing.

Why costs spiral out of reach

Cancer is among the most expensive diseases to treat. Newer targeted therapies and immunotherapies commonly carry list prices above $100,000 per year in the United States, and even well-insured patients can face annual out-of-pocket costs running into the thousands. Treatment also attacks the household budget from the other side: fatigue, surgery, and long courses of chemotherapy make it hard to keep working, and losing a job often means losing insurance coverage too.

Researchers call this combination “financial toxicity” — the idea that the economic damage of treatment itself produces measurable harm, including stress, depleted savings, lost homes, and, in extreme cases, bankruptcy. It is not a metaphor. One widely cited study found that cancer patients are 2.7 times more likely to file for bankruptcy than people never diagnosed with the disease.

The consequences are measured in lives

Skipping doses or abandoning treatment is not a neutral budget decision — it changes outcomes. A 2011 study of breast cancer patients found that those who stopped hormonal therapy earlier than scheduled, or took less than prescribed, were more likely to die. And the financial fallout carries its own mortality signal: a 2016 Journal of Clinical Oncology study found mortality rates 79 percent higher among cancer patients who declared bankruptcy compared with those who stayed solvent, even though the two groups had similar cancers and received the same treatments.

Oncologists have warned publicly that patients are being harmed daily by treatment costs, and that the deaths this causes are, in principle, preventable. Doctors increasingly say cost has to be part of the treatment conversation — not an afterthought left to the patient to manage alone.

What this looks like in Pakistan

Pakistan’s picture is arguably worse, because most care is paid for out of pocket and health insurance coverage is thin. A study by oncologists at Shaukat Khanum Cancer Memorial Hospital and Aga Khan University Hospital in Karachi found that for many patients, the average monthly cost of treatment far exceeded the family’s entire monthly household income, and a significant proportion described the financial burden as overwhelming.

Research on treatment abandonment in Pakistani childhood cancer care tells a similar story. A review of the Pakistani literature found a 22 percent abandonment rate driven by the high cost of care and the absence of support systems like counselling and psychosocial support — a figure that lines up strikingly with the global one-in-four pattern.

There is, however, one major exception in Pakistan: Shaukat Khanum itself. The hospital says that over 75 percent of its cancer patients are treated entirely free of cost, funded through Zakat contributions, donations, and its Patient Welfare Department. Each patient goes through a financial assessment, and support can cover the full cost of diagnosis, chemotherapy, surgery, and radiation for those who cannot pay. It is one of the largest charitable cancer-care operations of its kind — but it cannot absorb the country’s entire cancer burden, and it generally accepts patients who have not already started treatment elsewhere.

What can patients and families do?

No single tip fixes a broken financing system, but research and patient advocates point to steps that genuinely help:

• Ask about costs early. Oncologists increasingly expect — and welcome — questions about what treatment will cost. Knowing the price of each option before starting can change the plan.
• Check every assistance channel. Pharmaceutical patient-assistance programs, hospital welfare departments, Zakat funds, and charities such as Shaukat Khanum’s Patient Welfare Department and cancer-support NGOs exist specifically to close this gap.
• Do not cut doses silently. If a drug is unaffordable, tell the doctor before skipping doses. Abruptly stopping therapies like hormonal treatment can measurably worsen survival, and oncologists can sometimes switch to affordable generics or alternative regimens.
• Keep the receipts — literally. Documenting out-of-pocket spending strengthens applications for financial aid and helps families see where the money is actually going.